Vitamin K-2 and D-3 Supplementation During Zoledronic Acid Drug Holiday

Rationale for Supplementation During Drug Holiday

The American Society of Clinical Oncology recommends vitamin D supplementation (400-800 IU daily) for all patients receiving bone-modifying agents, including during treatment breaks 1, 3
Serum calcium must be monitored and maintained at adequate levels throughout the entire course of bone-modifying therapy, including during drug holidays, according to the Journal of Clinical Oncology guidelines 4, 5, 6

The American College of Clinical Oncology recommends calcium supplementation at 1,000-1,500 mg daily 1, 3
Vitamin D-3 supplementation is recommended at 400-800 IU daily (or 300,000 IU bolus prior to resuming zoledronic acid) 1
The National Institutes of Health suggests that vitamin K-2 and calcium should be separated by at least 2 hours to allow for maximum absorption of both nutrients 1

The American Society of Clinical Oncology recommends that serum calcium levels must be measured and any hypocalcemia corrected before restarting zoledronic acid 2, 3
Renal function assessment (serum creatinine and creatinine clearance >60 mL/min for full dose) is required prior to each zoledronic acid administration, according to the Journal of Clinical Oncology guidelines 4, 5, 6
The American Dental Association recommends that dental assessment should be completed before resuming therapy, with any pending dental procedures addressed beforehand to minimize osteonecrosis of the jaw (ONJ) risk 1, 4, 5

The National Osteoporosis Foundation advises against discontinuing calcium and vitamin D supplementation during drug holidays, as this increases risk of hypocalcemia when resuming bone-modifying therapy 1, 3
The American Gastroenterological Association recommends avoiding taking calcium supplements within 2 hours of oral medications or food that may interfere with absorption 1
The American Society of Clinical Oncology warns against resuming zoledronic acid without confirming adequate serum calcium levels, as hypocalcemia is a contraindication to bisphosphonate therapy 2, 3
The American Dental Association emphasizes the importance of ensuring dental health is optimized before restarting therapy, as invasive dental procedures during active bisphosphonate treatment significantly increase ONJ risk 1, 4, 5